HOME >> BIOLOGY >> NEWS
University of Pittsburgh reports best gene delivery to date of protein missing in Duchenne Muscular Dystrophy

PITTSBURGH, Nov. 27 Using sophisticated techniques, University of Pittsburgh scientists have engineered perhaps the best gene therapy to date for Duchenne Muscular Dystrophy (DMD), the catastrophic muscle wasting disease that strikes thousands of boys in the United States each year.

The research, conducted in animals and reported in the Nov. 28 issue of the Proceedings of the National Academy of Sciences, is remarkable on several fronts. The Pittsburgh team managed to whittle down the largest gene ever found (14 kilobases) and packaged its most important components (less than 4.2 kilobases) into the smallest and arguably the safest viral vector ever used for gene therapy.

With this work, the investigators demonstrated, for the first time, the minimal amount of the dystrophin gene needed to achieve functional muscle. The gene vector used was a genetically engineered form of adeno-associated virus, or AAV.

When injected into the calf muscles of mice unable to naturally produce the dystrophin protein, the mini-gene construct resulted in the expression of functional dystrophin protein in almost 90 percent of the muscle tissue treated. The dystrophin expression lasted at least one year the duration of the experiments.

Our research showed that we could introduce functional dystrophin into muscle tissue with AAV. This gives us great hope that we can use this gene therapy strategy in a larger animal model of DMD and eventually treat patients within several years, said Xiao Xiao, Ph.D., assistant professor in the department of molecular genetics and biochemistry at the University of Pittsburgh. We were excited to see that mice treated with the mini-dystrophin gene did not show evidence of muscle breakdown many months after treatment, and even after the treated mice exercised, as was seen in untreated mice that lack dystrophin.

With this work, Dr. Xiao and his laboratory have really taken the AAV vector to a new level in its application to the treat
'"/>

Contact: Lauren Ward
wardle@msx.upmc.edu
412-624-2607
University of Pittsburgh Medical Center
27-Nov-2000


Page: 1 2 3 4

Related biology news :

1. Indiana University, EPA to study airborne PCBs
2. University of Alberta researcher looks for clues to mysterious disease
3. Northeastern University receives $12.4 million NSF grant for creation of nanomanufacturing institute
4. Washington University in St. Louis leads group studying aging process
5. Tufts University establishes $4 million dollar tissue engineering resource center
6. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
7. As informatics grows, Indiana University helps set research agenda
8. University of Arizona licenses patent for natural fungicide
9. Washington University in St. Louis plays key role in sequencing moss genome
10. University of Pittsburgh receives $10 million grant for head and neck cancer
11. Clemson University spin-off uses corn to make plastics, provide cleaner air

Post Your Comments:
(Date:5/17/2013)... Research Foundation announced a new grant that intends to ... one of today,s most exciting areas of science, and ... Awards Panel selected Andrew T. Chan, MD, MPH and ... School, Boston, as the 2013 AGA-Elsevier Gut Microbiome Pilot ... funding, commencing in July 2013, to test the overarching ...
(Date:5/17/2013)... investigating the interaction of a group of proteins in ... have identified a new target that could increase cell ... University,s School of Biochemistry and published in the ... could eventually lead to new therapies for stroke and ... work by the team which identified a protein, known ...
(Date:5/17/2013)... Federation of American Societies for Experimental Biology (FASEB) released ... Health (NIH) funding trends highlighting the devastating impact of ... The FASEB analysis follows a May 15th Senate Appropriations ... who testified that the $1.6 billion cut the agency ... a substantial impact on the scientific community." , ...
Breaking Biology News(10 mins):New gut microbiome research to explore red meat -- colorectal cancer pathway 2SUMO wrestling cells reveal new protective mechanism target for stroke 2
(Date:5/20/2013)... (PRWEB) May 20, 2013 With bed bugs' ... said that although bed bugs need to be eliminated, one ... not compromise a person's health. And so to help bed ... to get rid of bed bugs without using ... bed bug spray it called Bed Bug Bully. , According ...
(Date:5/20/2013)... , May 20, 2013 Cempra, Inc. ... developing differentiated antibiotics to meet critical medical needs ... that it presented data at the American Thoracic ... Philadelphia demonstrating the antibacterial and enhanced ... prior Phase 2 clinical trial in outpatients with ...
(Date:5/20/2013)... BOSTON , May 20, 2013 Rhythm ... clinical trial of RM-131, the company,s novel ghrelin agonist ... diabetic patients. The trial demonstrated that RM-131 significantly accelerates ... in type 1 diabetic patients with diabetic gastroparesis. The ... conference in Orlando and recently ...
(Date:5/20/2013)... Researchers from the Southern University of Denmark ... and the acne causing P.acnes bacteria. Researchers believe found that ... out oxygen deprived location to seek shelter and grow. When ... the ability to live in the open joint areas, causing ... “ The best acne treatment ” explains why starting a ...
Breaking Biology Technology:New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 3Adult Acne Treatment, Probiotic Action Shares New Insight How Treating Acne May Help Reduce Body Pain 2
Cached News: